Associations Among Tremor Amplitude, Activities of Daily Living, and Quality of Life in Patients with Essential Tremor.


Journal

Tremor and other hyperkinetic movements (New York, N.Y.)
ISSN: 2160-8288
Titre abrégé: Tremor Other Hyperkinet Mov (N Y)
Pays: England
ID NLM: 101569493

Informations de publication

Date de publication:
2024
Historique:
received: 02 02 2024
accepted: 16 04 2024
medline: 6 5 2024
pubmed: 6 5 2024
entrez: 6 5 2024
Statut: epublish

Résumé

Essential tremor (ET) is a disabling syndrome consisting of tremor, primarily in the upper limbs. We assessed the correlation of The Essential Tremor Rating Assessment Scale (TETRAS) Performance Item 4 ratings of upper limb tremor with the TETRAS activities of daily living (ADL) subscale and with 2 quality of life (QoL) scales. This noninterventional, cross-sectional, point-in-time survey of neurologists(n = 60), primary care physicians (n = 38), and their patients with ET (n = 1,003) used real-world data collected through the Adelphi ET Disease Specific Programme™. Physician-reported measures (TETRAS Performance Item 4 and TETRAS ADL total) and patient-reported QoL measures (generic EuroQol-5 Dimension 5 Level [EQ-5D-5 L] and ET-specific Quality of Life in Essential Tremor Questionnaire (QUEST)) were assessed with bivariate and multivariable analyses. Sensitivity analyses were also conducted. The bivariate association between TETRAS Performance Item 4 score and TETRAS ADL total score was high (Pearson r = 0.761, This study showed that greater tremor severity (TETRAS Performance Item 4) was positively correlated with ADL impairment (TETRAS ADL) and negatively associated with QoL (EQ-5D-5 L and QUEST). TETRAS Performance Item 4 score is a robust predictor of TETRAS ADL total score, and TETRAS Performance Item 4 and TETRAS ADL total scores were robust predictors of the 2 QoL scales. The results demonstrate the value of TETRAS scores as valid endpoints for future clinical trials. This real-world study assessed TETRAS scores as predictors of impaired QoL in ET. TETRAS Performance Item 4 and ADL were associated with EQ-5D-5 L and QUEST. TETRAS scores may serve as valid endpoints for future clinical trials.

Sections du résumé

Background UNASSIGNED
Essential tremor (ET) is a disabling syndrome consisting of tremor, primarily in the upper limbs. We assessed the correlation of The Essential Tremor Rating Assessment Scale (TETRAS) Performance Item 4 ratings of upper limb tremor with the TETRAS activities of daily living (ADL) subscale and with 2 quality of life (QoL) scales.
Methods UNASSIGNED
This noninterventional, cross-sectional, point-in-time survey of neurologists(n = 60), primary care physicians (n = 38), and their patients with ET (n = 1,003) used real-world data collected through the Adelphi ET Disease Specific Programme™. Physician-reported measures (TETRAS Performance Item 4 and TETRAS ADL total) and patient-reported QoL measures (generic EuroQol-5 Dimension 5 Level [EQ-5D-5 L] and ET-specific Quality of Life in Essential Tremor Questionnaire (QUEST)) were assessed with bivariate and multivariable analyses. Sensitivity analyses were also conducted.
Results UNASSIGNED
The bivariate association between TETRAS Performance Item 4 score and TETRAS ADL total score was high (Pearson r = 0.761,
Discussion UNASSIGNED
This study showed that greater tremor severity (TETRAS Performance Item 4) was positively correlated with ADL impairment (TETRAS ADL) and negatively associated with QoL (EQ-5D-5 L and QUEST). TETRAS Performance Item 4 score is a robust predictor of TETRAS ADL total score, and TETRAS Performance Item 4 and TETRAS ADL total scores were robust predictors of the 2 QoL scales. The results demonstrate the value of TETRAS scores as valid endpoints for future clinical trials.
Highlights UNASSIGNED
This real-world study assessed TETRAS scores as predictors of impaired QoL in ET. TETRAS Performance Item 4 and ADL were associated with EQ-5D-5 L and QUEST. TETRAS scores may serve as valid endpoints for future clinical trials.

Identifiants

pubmed: 38708124
doi: 10.5334/tohm.877
pmc: PMC11067966
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

22

Informations de copyright

Copyright: © 2024 The Author(s).

Déclaration de conflit d'intérêts

Margaret E Gerbasi reports financial support was provided by SAGE Therapeutics Inc. Margaret E Gerbasi reports financial support was provided by Biogen. Margaret E Gerbasi reports a relationship with SAGE Therapeutics Inc that includes: employment and equity or stocks. Rodger J Elble reports a relationship with Applied Therapeutics Inc that includes: consulting or advisory. Rodger J Elble reports a relationship with Attune that includes: consulting or advisory. Rodger J Elble reports a relationship with Cadent Medical Communications that includes: consulting or advisory. Rodger J Elble reports a relationship with Cavion that includes: consulting or advisory. Rodger J Elble reports a relationship with Cydan that includes: consulting or advisory. Rodger J Elble reports a relationship with Five Microns that includes: consulting or advisory. Rodger J Elble reports a relationship with Jazz Pharmaceuticals Inc that includes: consulting or advisory. Rodger J Elble reports a relationship with Osmotica Pharmaceuticals LLC that includes: consulting or advisory. Rodger J Elble reports a relationship with Praxis Precision Medicines Inc that includes: consulting or advisory. Rodger J Elble reports a relationship with SAGE Therapeutics Inc that includes: consulting or advisory. Eddie Jones reports a relationship with Adelphi Real World that includes: employment. Alexander Gillespie reports a relationship with Adelphi Real World that includes: employment. John Jarvis reports a relationship with Medicus Economics that includes: employment. John Jarvis reports a relationship with SAGE Therapeutics Inc that includes: consulting or advisory. John Jarvis reports a relationship with Biogen that includes: consulting or advisory. Elizabeth Chertavian reports a relationship with Medicus Economics that includes: employment. Elizabeth Chertavian reports a relationship with SAGE Therapeutics Inc that includes: consulting or advisory. Elizabeth Chertavian reports a relationship with Biogen that includes: consulting or advisory. Zachary Smith reports a relationship with Medicus Economics that includes: employment. Zachary Smith reports a relationship with SAGE Therapeutics Inc that includes: consulting or advisory. Zachary Smith reports a relationship with Biogen that includes: consulting or advisory. Mina Nejati reports a relationship with Biogen that includes: employment and equity or stocks. Ludy C Shih reports a relationship with WCG MedAvante that includes: consulting or advisory. Ludy C Shih reports a relationship with Encora Therapeutics that includes: consulting or advisory.

Auteurs

Margaret E Gerbasi (ME)

Sage Therapeutics, Inc., Cambridge, MA, USA.

Rodger J Elble (RJ)

Southern Illinois University School of Medicine, Springfield, IL, USA.

Eddie Jones (E)

Adelphi Real World, Adelphi Mill, Bollington, United Kingdom.

Alexander Gillespie (A)

Adelphi Real World, Adelphi Mill, Bollington, United Kingdom.

John Jarvis (J)

Medicus Economics, Milton, MA, USA.

Elizabeth Chertavian (E)

Medicus Economics, Milton, MA, USA.

Zachary Smith (Z)

Medicus Economics, Milton, MA, USA.

Mina Nejati (M)

Biogen, Cambridge, MA, USA.

Ludy C Shih (LC)

Boston University School of Medicine, Boston, MA, USA.
Boston Medical Center, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH